Genprex sees newly licensed diabetes gene therapy as an "opportunity we couldn"t pass up" – Proactive Investors USA & Canada

Posted: February 14, 2020 at 5:46 pm

Genprex Inc () CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could have the potential to treat Type 1 and Type 2 diabetes.

Varner says the newly licensed diabetes gene therapy was an 'opportunity we couldn't pass up' because of its large market opportunity and 'massive' medical need.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

More:
Genprex sees newly licensed diabetes gene therapy as an "opportunity we couldn"t pass up" - Proactive Investors USA & Canada

Related Posts